TY - JOUR
T1 - Acute kidney injury and disease
T2 - Long-term consequences and management
AU - Rangaswamy, Dharshan
AU - Sud, Kamal
N1 - Funding Information:
KS has received speaker’s honoraria from Baxter Healthcare, Roche, Amgen and Boehringer Ingelheim and conference or meeting sponsorships from Shire, Roche, Boehringer Ingelheim, Amgen, Sanofi and Novartis. DR has received a grant from the International Society of Nephrology and does not have any other conflicts of interest to declare.
Publisher Copyright:
© 2018 Asian Pacific Society of Nephrology
PY - 2018/11
Y1 - 2018/11
N2 - With increasing longevity and the presence of multiple comorbidities, a significant proportion of hospitalized patients, and an even larger population in the community, is at increased risk of developing an episode of acute kidney injury (AKI). Because of improvements in short-term outcomes following an episode of AKI, survivors of an episode of AKI are now predisposed to develop its long-term sequel. The identification of risk for progression to chronic kidney disease (CKD) is complicated by the absence of good biomarkers that identify this risk and the variability of risk associated with clinical factors including, but not limited to, the number of AKI episodes, severity, duration of previous AKI and pre-existing CKD that has made the prediction for long-term outcomes in survivors of AKI more difficult. Being a significant contributor to the growing incidence of CKD, there is a need to implement measures to prevent AKI in both the community and hospital settings, target interventions to treat AKI that are also associated with better long-term outcomes, accurately identify patients at risk of adverse consequences following an episode of AKI and institute therapeutic strategies to improve these long-term outcomes. We discuss the lasting renal and non-renal consequences following an episode of AKI, available biomarkers and non-invasive testing to identify ongoing intra-renal pathology and review the currently available and future treatment strategies to help reduce these adverse long-term outcomes.
AB - With increasing longevity and the presence of multiple comorbidities, a significant proportion of hospitalized patients, and an even larger population in the community, is at increased risk of developing an episode of acute kidney injury (AKI). Because of improvements in short-term outcomes following an episode of AKI, survivors of an episode of AKI are now predisposed to develop its long-term sequel. The identification of risk for progression to chronic kidney disease (CKD) is complicated by the absence of good biomarkers that identify this risk and the variability of risk associated with clinical factors including, but not limited to, the number of AKI episodes, severity, duration of previous AKI and pre-existing CKD that has made the prediction for long-term outcomes in survivors of AKI more difficult. Being a significant contributor to the growing incidence of CKD, there is a need to implement measures to prevent AKI in both the community and hospital settings, target interventions to treat AKI that are also associated with better long-term outcomes, accurately identify patients at risk of adverse consequences following an episode of AKI and institute therapeutic strategies to improve these long-term outcomes. We discuss the lasting renal and non-renal consequences following an episode of AKI, available biomarkers and non-invasive testing to identify ongoing intra-renal pathology and review the currently available and future treatment strategies to help reduce these adverse long-term outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85053019540&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053019540&partnerID=8YFLogxK
U2 - 10.1111/nep.13408
DO - 10.1111/nep.13408
M3 - Review article
C2 - 29806146
AN - SCOPUS:85053019540
SN - 1320-5358
VL - 23
SP - 969
EP - 980
JO - Nephrology
JF - Nephrology
IS - 11
ER -